Oramed Pharmaceuticals (ORMP) Financials

$5.01

$0.08 (1.62%)

As on 04-Sep-2026 16:00EDT

Market cap

$208 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

1.2

P/B Ratio

0.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Operating Revenue	--	2.00	--	1.34	2.70	2.70
Cost of Revenue	0.09	1.99	0.19	--	--	--
Gross Profit	-0.09	0.01	-0.19	1.34	2.70	2.70
Operating Expenses	14.46	15.10	12.78	17.11	43.30	43.30
Operating Profit (EBIT)	-14.52	-15.09	-12.78	-15.77	-40.60	-40.60
Other Income	--	--	--	--	--	--
Profit before Tax	220.28	75.32	-15.92	5.09	-37.66	-37.66
Provision for Tax	45.41	11.31	3.18	--	0.10	0.10
Profit after Tax (Net Income)	174.87	64.05	-19.06	5.53	-37.76	-37.76
Minority Interest	0.01	0.03	0.04	0.44	1.14	1.20
Consolidated Profit	--	--	--	--	--	--

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Shareholder's Funds	317.47	199.74	146.27	163.82	151.81	151.81
Minority Interest	0.01	--	--	--	--	--
Non-Current Liabilities	41.44	12.03	4.25	4.44	4.74	4.74
Current Liabilities	10.73	19.09	5.69	53.21	5.75	5.75
Total Liabilities	380.37	230.86	155.28	220.55	161.64	161.64

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Non-Current Assets	316.24	97.59	12.06	57.97	4.53	4.53
Current Assets	53.41	133.27	143.22	162.58	157.11	157.11
Total Assets	380.37	230.86	155.28	220.55	161.64	161.64
Total Debt*	0.73	0.83	0.37	51.62	0.89	0.89
Net Current Assets	42.68	114.19	137.54	109.37	109.37	151.36

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Cash From Operating Activities	--	-9.15	-8.41	-10.30	-27.92	-28.70
Cash Flow from Investing Activities	--	5.44	105.82	-73.04	--	30.21
Cash from Financing Activities	--	-4.74	-52.04	51.98	10.78	11.56
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Adjusted EPS ($)	4.13	1.58	-0.48	0.14	--	-0.97
Cash EPS ($)	4.13	1.59	-0.47	0.14	--	-0.97
Adjusted Book Value ($)	7.68	4.94	3.66	4.06	--	3.89
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.23	-0.21	-0.25	--	-0.74
Free Cash Flow per Share ($)	--	-0.27	-0.21	-0.26	--	-0.75

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
ROCE (%)	--	36.89	-10.53	3.00	-24.73	-49.41
ROE (%)	67.62	37.02	-12.29	3.50	-24.88	-49.70
ROA (%)	64.08	33.17	-10.14	2.89	-23.36	-46.72
EBIT Margin (%)	--	3,766.20	--	531.72	-1,501.96	-1,501.96
Net Margin (%)	--	3,202.50	--	412.31	-1,397.11	-1,397.11
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Revenue Growth (%)	--	--	-1.00	-0.50	--	--
EBIT Growth (%)	472.09	599.93	-311.47	117.55	--	-67.60
Net Profit Growth (%)	825.60	436.04	-444.98	114.63	-3.29	-69.82
EPS Growth (%)	778.85	4.32	-4.49	1.14	--	-0.59
Book Value Growth (%)	105.97	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Price / Earnings	1.21	1.80	-5.07	16.88	--	-12.44
Price / Book Value	0.65	0.58	0.66	0.57	--	3.09
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.52	-0.13	3.02	-2.34	4.19	-8.52
Close Price ($)	4.81	2.85	2.42	2.31	3.28	12.03
High Price ($)	5.19	3.24	3.67	13.73	13.73	14.77
Low Price ($)	1.98	1.82	2.00	1.67	1.81	3.59
Market Cap ($ Cr)	208.40	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Debt to Equity	--	0.00	0.00	0.32	0.01	0.01
Short term debt to equity ratio	0.00	0.00	0.00	0.31	0.00	0.00
Current Ratio	4.98	6.98	25.19	3.06	27.34	27.34
Quick Ratio	4.98	--	--	--	--	--
Interest Coverage	654.64	--	-17.66	1.99	-13.84	-13.84

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Aug-23	Dec-22	Aug-22	Dec-21	Aug-21	Dec-20	Aug-20
Debtors to sales (%)	--	231.80	--	--	--	--
Asset Turnover	--	0.01	--	0.01	0.02	0.03
Receivable days	--	846.65	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	113.23	1,267.97	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.